CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it will expand its preclinical program to include liver cancers, specifically rare stem cell-like forms of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Patients with these stem cell-like tumors have a significantly worse survival than patients with more traditional liver tumors
CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform designed to use the body’s immune system to treat cancer, today announced the successful creation of its nanoparticle that can target specific cells that are potentially cancerous
CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to fight cancer, today announced that two of its lead scientists, Dr. George Katibah and Dr. Adam Grant, were recently featured on Cytiva’s influential podcast series, Discovery Matters. The episode highlights CancerVax’s revolutionary approach to immunotherapy and its mission to create a therapy that can universally target and destroy cancer cells
CancerVax, Inc., the developer of a revolutionary universal cancer treatment platform that will use the body’s immune system to treat cancer, announced today that Sumant Ramachandra, MD, PhD, MBA and founder of SR Global Health, LLC, a healthcare advisory firm, will serve as the Company’s new Chief Scientific Advisor
